STORM Therapeutics is a University of Cambridge spin-out translating the ground-breaking work of Professors Tony Kouzarides and Eric Miska in RNA epigenetics into the discovery of first-in-class drugs in oncology and other diseases.
In May 2019, STORM announced it had raised an additional £14 million – taking its total Series A round to £30m.
The financing included an injection from new investor Seroba Life Sciences in Dublin. Existing investors Cambridge Innovation Capital, M Ventures, Pfizer Ventures, Taiho Ventures and IP Group also participated in the fundraise. The funding will enable STORM to advance its broad pipeline further in preclinical development and accelerate its programmes towards the clinic.
Professor Kouzarides has a strong entrepreneurial track record. He was a co- founder of Abcam plc in Cambridge and co-founder of UK-based cancer drug discovery company Chroma Therapeutics, based in Oxford.